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Background: Transglutaminase-4 (TGase-4), also known as the Prostate Transglutaminase, is an enzyme found to
be expressed predominately in the prostate gland. The protein has been recently reported to influence the
migration and invasiveness of prostate cancer cells. The present study aimed to investigate the influence of TGase-4
on cell-matrix adhesion and search for the candidate active domain[s] within the protein.
Methods: Human prostate cancer cell lines and prostate tissues were used. Plasmids that encoded different
domains and full length of TGase-4 were constructed and used to generate sublines that expressed different
domains. The impact of TGase-4 on in vitro cell-matrix adhesion, cell migration, growth and in vivo growth were
investigated. Interactions between TGase-4 and focal adhesion complex proteins were investigated using
immunoprecipitation, immunofluorescence and phosphospecific antibodies.
Results: TGase-4 markedly increased cell-matrix adhesion and cellular migration, and resulted in a rapid growth
of prostate tumours in vivo. This effect resided in the Core-domain of the TGase-4 protein. TGase-4 was found to
co-precipitate and co-localise with focal adhesion kinase (FAK) and paxillin, in cells, human prostate tissues and tumour
xenografts. FAK small inhibitor was able to block the action mediated by TGase-4 and TGase-4 core domain.
Conclusion: TGase-4 is an important regulator of cell-matrix adhesion of prostate cancer cells. This effect is
predominately mediated by its core domain and requires the participation of focal adhesion complex proteins.
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Prostate transglutaminase, also known as transglutaminse-
4 (TGase-4), is a member of the transglutaminase [EC
2.3.2.13] family. Similar to some of the members, such as
keratinocyte TGase, TGase-4 has a relatively restricted pat-
tern of distribution in the body, namely, confined to the
prostate gland [1-3]. The role of TGase-4 is not entire clear.
Although early studies, mostly using a single technique,
have shown that TGase-4 may be reduced in prostate* Correspondence: jiangw@cf.ac.uk
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reproduction in any medium, provided the orcancer, in comparison with normal prostate tissues
[4,5], recent studies have indicated otherwise. Most
interestingly, we and others have recently shown that
levels of TGase-4 in prostate cancer cells may be linked
to the aggressiveness of the cells. For example, over-
expression of TGase-4 in prostate cancer cells increases
the invasiveness and the migration of prostate cancer
cells. Vice versa, knocking down TGase-4 from TGase-4
positive prostate cancer cells rendered the cells less ag-
gressive [6]. Furthermore, levels of TGase-4 in prostate
cancer cells are amongst factors that influence the cell’s
response to other molecules, namely MDA-7/IL-24 and
HGF-L/MSP-1 [7,8].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Jiang et al. Journal of Translational Medicine 2013, 11:269 Page 2 of 12
http://www.translational-medicine.com/content/11/1/269The influence of TGase-4 on cell invasiveness and
migration is not an isolated observation in the TGase
family. For example, tissue TGase (TGase-2) has been
shown to be a possible coreceptor for cancer cell-matrix ad-
hesion and that impairment of TGase-2 increases the adhe-
sion to matrix and migration over matrix [9]. TGases have
been implicated in the development of cancer and metasta-
sis [10]. TGase-2 was found to exist at much higher levels
of drug resistant cancer cells and in patients who developed
drug resistance [11]. TGases are also involved in regulat-
ing apoptosis [12], which may be linked to the fact that
TGase-2 is a caspase substrate during apoptosis [13] and
a substrate of Calpain [14]. Another calcium regulator,
psoriasin (S100A7) is also a substrate of TGase-2 [15].
Matrix invasiveness and the migratory ability of can-
cer cells are associated with a number of extracellular
and intracellular events. Critical to the invasion and
migration of cancer cells is cell-matrix adhesion [16,17].
Cell-matrix adhesion is an essential cellular function in
pathophysiological processes of the body; and as previ-
ously established in the past decades, cell-matrix adhe-
sion is largely mediated by a group of transmembrane
proteins, namely integrins which are formed by the
heterodimeric combination of subunit proteins (alpha-
and beta- units). The interaction between integrins and
the extracellular matrix not only provides a mechanical
mechanism for cells to be attached to matrix and the
body structure, it is also essential to mediating the sig-
naling of the cells, allowing communication between the
extracellular and intracellular environment.
The intriguing role of TGase-4 in prostate cancer cells,
namely the involvement in the invasion and motility,
indicated that a potential link underlying this critical
function of the enzyme may be cell-matrix adhesion. Here,
we report that TGase-4 is indeed involved in the matrix
adhesion of prostate cancer cells. This action of TGase-4
appears to rely on the TGase-4 core domain and poten-
tially via the FAK pathway. Knowledge of this molecular
and cellular link may prove useful in consideration of the
development of therapeutic modalities for prostate cancer.
Methods
Materials and cell lines
Human prostate cancer cells, PC-3 and CA-HPV-10 were
from ATCC (American Type Cell Collection, Manassas,
VA, USA). Fresh frozen human prostate tissues (normal
and tumour), were collected from University Hospital of
Wales under the approval of local ethical committee (South
East Wales Local Research Ethics Committee, Protocol
Number - 03/5048). Written consents were obtained from
the patients. Tissues were obtained immediately after sur-
gery and stored at −80°C until use.
Monoclonal antibodies of human FAK and paxillin
were from Transduction laboratories and a neutralisingmonoclonal antibody to β1-integrin was obtained from
R&D Systems Europe (Abbingdon, England). Phospho-
specific antibody to FAK and paxillin were from Santa Cruz
Biotechnologies, Inc. Rabbit and rat anti-human TGase-4
antibodies were from Abcam (Cambridge, England, UK),
Santa-Cruz Biotechnologies Inc., (Santa Cruz, CA, USA)
and Abnova (Taipei, Taiwan), respectively. Recombinant
human TGase-4 [rhTGase-4] was from Abnova (Taipei,
Taiwan). Fluorescence and HRT-conjugated secondary anti-
bodies were from Sigma-Aldrich [Poole, Dorset, England,
UK]. Small inhibitor to FAK [FP-573228] was from Tocris
Biochemicals (Bristol, England, UK) and Santa Cruz Bio-
technologies, Inc., (Santa-Cruz, California, USA], respect-
ively. Monoclonal antibody to phosphotyrosine (PY20),
monoclonal anti-GAPDH and protein A/G agarose were
from Santa-Cruz Biotechnologies, Inc. (Santa Cruz, CA,
USA). Recombinant human hepatocyte growth factor/
scatter factor (HGF/SF) was a gift from Dr. T. Nakamura
(Osaka University Medical School, Osaka, Japan). Matrigel
(reconstituted basement membrane) was purchased from
Collaborative Research Products (Bedford, Massachusetts,
USA). Transwell plates equipped with a porous insert
[pore size 8 μm] were from Becton Dickinson Labware
(Oxford, UK). DNA gel extraction and plasmid extraction
kits were from Sigma-Aldrich (Poole, Dorset, England,
UK). All other chemicals were from Sigma-Aldrich (Poole,
Dorset, England, UK) unless stated otherwise.
Construction of hammerhead ribozyme transgenes
targeting the human prostate-transglutaminase and
mammalian expression vector for human prostate
transglutaminase (TGase-4)
Hammerhead ribozymes that specifically target a GTC site
of the human prostate TGase-4 (GenBank accession
NM_003241), based on the secondary structure of TGase-4,
have been generated as previously described [6]. Touch-
down PCR was used to generate the ribozymes with the re-
spective primers [Additional file 1]. This was subsequently
cloned into a pEF6/V5-His vector (Invitrogen, Paisley,
Scotland, UK; selection markers: ampicillin and blasticidin,
for prokaryotic and mammalian cells, respectively). After
identification of the colonies with correct inserts using dir-
ection specific PCR, the colony was amplified. Following
purification and verification, the extracted plasmids were
subsequently used for transfecting prostate cancer cells by
way of electroporation (Easyjet, Flowgen, England, UK).
Following selection of transfected cells with blasticidin
(used at 5 μg/ml) and verification, the following stably trans-
fected cells were established: TGase-4 knock-down cells
[designated here as CA-HPV-10ΔTGase4 in this manuscript],
plasmid only control cells (CA-HPV-10pEFa), and the wild
type, CA-HPV-10WT. The CA-HPV-10ΔTGase4 and the CA-
HPV-10pEFa cells thus created were always kept in a main-
tenance medium which contained 0.5 μg/ml blasticidin.
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from a cDNA library of human prostate tissues using
primers listed in Additional file 1. Reverse transcription was
carried out using a RT kit (Sigma-Aldrich, Poole, Dorset,
England, UK) and amplification using an extensor PCR
master mix which has an additional proof reading polymer-
ase (AbGene, Ltd., Surrey, England, UK). The TGase-4 full
length coding product was similarly cloned into the
pEF6 vectors. PC-3 cells which express little TGase-4
were transfected with either the control vector or
TGase-4 expression vector. Stably transfected cells were
designated as PC-3pEF/His and PC-3TGase4exp, for control
transfection and TGase-4 expression, respectively. In
subsequent experiments, the mixture of multiple clones
for each stably transfected cells were used.
Creation of sublines of PC-3 cells which expressed
mutant TGase-4
The following TGase-4 mutant constructs were generated
from human prostate cDNA library: TGase-N domain
deleted (TG4ΔN, amino acids 8–123 deleted), TGase-C
domain deleted [TG4ΔC, amino acid 585–684 deleted],
TGase-core expression only (TG4CoreLarge, containing
amino acids 124–585), and TGase-core central region
(TG4CoreSmall, containing amino acids 260–353), TGase-
4 N-domain only (TG4ΔN/core) and TGase-4 C-domain
only (TG4ΔC/core), using the pEF6 vector. Primers used
are listed in Additional file 1. PC-3, negative for TGase-4
was transfected with the plasmids with mutant TGase-4
and selected and verified for the expression of mutant
TGase-4 by way of RT-PCR. Stably transfected cells, desig-
nated: PC3TG4ΔN, PC3TG4ΔC, PC3TG4ΔN/core, PC3TG4ΔC/core,
PC3TG4CoreLarge and PC3TG4CoreSmall were used in the sub-
sequent assays.
RNA preparation and RT-PCR
RNA from cells was extracted using an RNA extraction
kit (AbGene Ltd., Surrey, England, UK) and concentration
quantified using a spectrophotometer (Wolf Laboratories,
York, England, UK). cDNA was synthesised using a first
strand synthesis with an oligodt primer (AbGene, Surrey,
UK). The polymerase chain reaction (PCR) was performed
using sets of primers (Additional file 1) with the following
conditions: 5 min at 95°C, and then 20 sec at 94°C-25 sec-
onds at 56°C, 50 sec at 72°C for 36 cycles, and finally 72°C
for 7 min. ß-actin was amplified and used as a house keep-
ing control. PCR products were then separated on a 0.8%
agarose gel, visualised under UV light, photographed using
a Unisavetm camera [Wolf Laboratories, York, England,
UK] and documented with Photoshop software.
Quantitative analysis of tranglutaminase
The level of the prostate TGase transcripts in the
above-prepared cDNA was determined using a real-timequantitative PCR, based on the AmplifluorTM technology
that was modified from previous reported [18]. Briefly,
pairs of PCR primers were designed using the Beacon
Designertm software (version 2, Palo Alto, California, USA)
(Additional file 1), but added to one of the primers was an
additional sequence, known as the Z sequence (5′actgaacct-
gaccgtaca′3) which is complementary to the universal Z
probe (Intergen Inc., Oxford, England, UK). The reaction
was carried out using the following: Hot-start Q-master
mix (AbGene, Ltd., Poole, Dorset, England, UK), 10 pmol
of specific forward primer, 1 pmol reverse primer which
has the Z sequence (underlined) (Additional file 1), 10 pmol
of FAM-tagged probe, and cDNA generated from approxi-
mately 50 ng RNA. The reaction was carried out using
IcyclerIQtm (Bio-Rad, Hammel Hemstead, England, UK)
which was equipped with an optic unit that allows real time
detection of 96 reactions. The following condition was
used: 94°C for 12 min, 50 cycles of 94°C for 15 sec, 55°C
for 40 sec and 72°C for 20 sec. The levels of the transcripts
were generated from an internal standard that was simul-
taneously amplified with the samples.
In vitro cell growth assay
This was based on a previously reported method [19]. Cells
were plated into 96-well plated at 2,000 cells/well followed
by a period of incubation. Cells were fixed in 4% formalde-
hyde at the day of plating and daily for the subsequent
5 days. 0.5% crystal violet (w/v) was used to stain cells. Fol-
lowing washing, the stained crystal violet was dissolved with
10% (v/v) acetic acid and the absorbance was determined at
a wavelength of 540 nm using an ELx800 spectrophotom-
eter. Absorbance represents the cell number.
Cell-matrix adhesion assay
This was based on a previously reported method [19].
Briefly, tissue culture 96-well plates (Greiner Laboratories,
Gloucester, England) were precoated with 5 μg Matrigel.
After rehydration of the well with Matrigel, 10,000 cells
[transfected and controls] were added to each well. After
incubating the plates for 40 min in an incubator, culture
medium and non-adherent cells were disregarded. The
plates were then washed 5 times with a sterile BSS buffer
and added with 4% formalin for more than 30 min. 0.5%
of crystal violet was used to stain the cells. After washing,
the number of cells adhered to Matrigel coated surface
was counted under a microscope and is shown here as the
number of adherent cells per field.
Electric cell-substrate impedance sensing (ECIS) based cell
adhesion assay
ECIS Zθ model was used in the present study and for cell
modelling. Cells were monitored at 1,000, 2,000, 4,000,
8,000, 16,000, 32,000 and 64,000Hz. The adhesion was
analysed by the integrated Rb modelling method [20-22].
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Cells were grown in 25 cm2 flasks and removed by cell
scrapper. After centriguation (2000 rpm), media were
removed and cell pellets were lysed using a lysis buffer
(50 mM Tris, 150 mM NaCl, pH 8.0, with the following
addition: 1% Triton, 0.1% SDS, 2 mM CaCl2, 100 μg/ml
phenylmethylsulfonyl fluoride, 1 μg/ml leupeptin, 10 mM
sodium orthovanadate and 1 μg/ml aprotinin). Fresh frozen
human prostate tissues, Normal and Tumour, were homo-
genised in a HCMF buffer. Proteins from cells and tissues
were quantified, diluted to same concentration, and mixed
with sample buffer before boiling. For phosphorylation
study, cells were subject to serum hunger for 2 hrs, before
rhTGase-4 was added. Medium alone, medium with con-
trol buffer, BSS plus 0.1% BSA, or Sodium orthovanadate
(1 mM with 0.1% H2O2) were used as the respective nega-
tive and positive control. After one hour, cells were har-
vested and lysed. To each cell lysate was added anti-FAK,
anti-paxillin, anti-integrin-ß1, or anti-TGase-4 antibodies.
After the immunocomplex was precipitated using protein
A/G agarose, the protein was separated on 8% SDS PAGE
and the respective phosphorylated bands probed with
anti-phosphotyrosine antibody (PY20) and potentially co-
precipitated TGase-4 was probed with anti-TGase-4 anti-
body. For the protein interaction analysis, protein lysates
from TGase-4 positive CA-HPV-10 cells and from prostate
tissues were similarly added. The antibodies for immunopre-
cipitation and the precipitate were similarly probed by anti-
TGase-4 antibody. GAPDH was used as loading control.
In vivo tumour model
In vivo studies were reviewed by Biological Standard and
Experimental Animal Application Ethics Committee of
Cardiff University and conducted under the British Home
Office project license (PIL 30/5509 and PPL 30/2591).
Animal Welfare were fully observed in accordance with
the United Kingdom Coordinating Committee for Cancer
Research (UKCCCR) guidelines for the welfare of animals
in experimental neoplasia (www.ncrndev.org.uk).
Athymic nude mice (CD-1, Charles River Laboratories)
were injected via subcutaneous route, prostate cancer cells
(control and TGase-4 transfected) at 0.5 million per 100 μl
solution which contained 2 mg/ml Matrigel (n = 6 per
group). Tumours were monitored weekly for a period of
4 weeks. The size of tumours were measured using a digital
caliper. The volume of tumours were calculated by lengthx-
widthx0.54. At the end of the experiments, tumours were
dissected and stored at −80°C and subsequently processed
for molecular and histological analysis.
Immunofluorescence staining of TGase-4, FAK, paxilliln
and β1-integrin in cells and tissues
Frozen sections of prostate tissues (normal and tumour)
and tumour xenografts were cut at a thickness of 6 μmusing a cryostat. The sections were mounted on super
frost plus microscope slides, air dried and then fixed in a
mixture of 50% Acetone and 50% methanol. The sections
were then placed in “Optimax” wash buffer for 5 –10 min
to rehydrate. Sections were incubated for 20 min in a 1%
horse serum blocking solution and probed with the primary
antibodies (anti-FAK, anti-Paxillin and anti-integrin at
1:400, anti-TGase-4 at 1:250 dilutions). Following exten-
sive washings, sections were incubated for 30 mins in
the secondary FITC- and TRITC conjugated antibodies
(1:1,000) in the presence of Hoescht33258 at 10 μg/ml
(Sigma-Aldrich, Poole, Dorset, England, UK). For dual
immunofluorescence staining, mouse monoclonal anti-
FAK, Paxillin or integrin was added together with
rabbit anti-TGase-4 antibody. Secondary antibodies
were TRITC-conjugated anti-mouse IgG and FITC-
conjugated anti-rabbit IgG mixture. Following extensive
washings, the slides were mounted using Flurosavetm
mounting media (Calbiochem, Nottingham, UK) and
allowed overnight in fridge to harden, before being exam-
ined. Slides were examined using a Olympus fluorescence
microscope and photographed using a Hamamatsu digital
camera. The images were documented using the Cellysis
software (Olympus). Photoshop CS6 was used to produce a
merge image from the dual stained images.
Statistical analysis was carried out using SigmaPlot
(version 11). Mann–Whitney U test or ANOVA on rank,
and Student’s “t” test were respectively used for skewed
and abnormally distributed data.
Results
Manipulation of TGase-4 in prostate cancer cells
We previously reported, sublines of CA-HPV-10, which
expressed highl levels of TGase-4, were transfected with
the anti-TGase-4 ribozyme transgene. Cells which had
virtually lost the TGase-4 transcript as the result of the
transgene, were selected and verified. These cells have
been named CA-HPV-10ΔTGase4. PC-3 cells which were
largely TGase-4 negative, were transfected with TGase-4
expression vector. Stably transfected cells were established
and over-expression of TGase-4 in the cells verified, the
cells now termed – PC-3TGase4exp (Figure 1A). It was in-
teresting to observe that expression of TGase-4 had little
bearing to the growth rate of both cells (Figure 1B).
The nature of TGase-4 expression is linked to the
adhesion properties of prostate cancer cells
Over-expression of TGase-4 in PC-3 prostate cancer
cells increased the adhesiveness to matrix (Figure 1C),
accompanied by an increase in matrix invasion of the
cells. Of the two over-expressing sublines, PC-3TGase4exp3
and PC-3TGase4exp13, PC-3TGase4exp3 had a more pro-
found effect on matrix adhesion and was used in subse-
quent experiments. Likewise, knockdown TGase-4 from
Figure 1 Effects of TGase-4 expression and cell-matrix adhesion of prostate cancer cells. A and B: Western blotting analysis of protein
expression of TGase-4 after transfections for PC-3 (A) and CA HPV-10 (B) cells. Bottom panel is the TGase-4/GAPDH ratio. C: Over-expression of
TGase-4 in PC-3 cells signficantly increased matrix adhesion. *p < 0.05 vs no HGF, ** p < 0.05 vs control cells. D: Effects of TGase-4 knockdown on
the in vivo invasiveness of CA-HPV-10 cells. Reduction of TGase-4 significantly reduced the invasiveness of the prostate cancer cells. *p < 0.05 vs
no HGF, ** p < 0.05 vs control cells. E and F: ECIS based analysis of matrix adhesion of PC-3 (E) and CA-HPV-10 (F) cells. Over-expression of
TGase-4 in PC-3 cells markedly increased the pace of matrix adhesion compared with the control cells (E). In contrast, knocking down TGase-4
marked reduced the adhesiveness.
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and invasion [Figure 1D: * p < 0.05 vs no HGF, ** p < 0.05
vs control cells, by non-paired t test]. The same was
reflected in the ECIS adhesion assay as shown in Figures 1E
and 1F, in that knocking down TGase-4 from CA-HPV-10
dramatically reduced the resistance (31.17 ± 25.1Ω)
compared with control [p = 0.042, by non-paired t test]
(Figure 1F). In contrast, over-expressing TGase-4 in
PC-3 resulted in an increase in the electrical resistance
(Figure 1E).The potential role for integrin and FAK in TGase-4
mediated cell adhesion
TGase-4 associated cell adhesion and cellular motion
was highly dependent on integrin. Anti-ß1-integrin
was found to reduce the cell matrix adhesion of control
PC-3 cells by 27.6% (p = 0.17, by non-paired t test) using
an ECIS analysis. However, PC-3 cells over-expressing
TGase-4 showed a 53.9% dramatic reduction in the
adhesion by anti-ß1 integrin antibody (8.92 ± 3.3Ω
for PC-3TGase4exp control antibody vs 4.1 ± 1.82Ω for
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by non-paired t test).
To further evaluate the signalling events in TGase-4
mediated matrix adhesion, we used a selective small in-
hibitor to FAK. Here, we evaluated PC-3 cells under
the following settings: comparing the response of PC-3
and PC-3TGase4exp to the FAK inhibitor, and comparing
the response of PC-3 and CA-HPV-10 control cells to
the FAK inhibitor in the presence and absence of ex-
ogenous TGase-4 (rhTGase-4). Shown in Figure 2A are
ECIS based cell adhesion assay modelled using the Rb
method. Compared with the wild type and the control
cells, PC-3TGase4exp cells showed a rapid and significant
increase in cell adhesion. The data from these experiments
are shown in Figure 2B. All three cells responded to the
FAK inhibitor FP-573228 by reducing the adhesive-
ness. The inhibitory effect is particularly strong with
PC-3TGase4exp cells. Exogenous rhTGase-4 significantly
increased the adhesiveness in both PC-3 and CA-HPV-
10 cells (Figure 2C/D). This increase in response to
rhTGase-4 was significantly reverted by FP-573228.
Exogenous TGase-4 induced activation of focal adhesion
kinase and paxillin
To evaluate the activation status of focal adhesion complex,
cells were treated with exogenous rhTGase-4. Figure 3 (left)
shows the phosphorylation on tyrosine residues of FAK and
paxillin in PC-3 (left) and CA-HPV-10 (right) cells. The
low grade of tyrosine phosphorylation of FAK in both cells
was markedly activated by rhTGase-4. The same, but to a
lesser degree, activation of paxillin was also seen. To further
explore the relationship between the focal adhesion com-
plex proteins and TGase-4, immunoprecipitation was car-
ried out. Both FAK and paxillin were found to be able to
precipitate TGase-4 from both prostate tissue protein lysate
and from CA-HPV-10 cells which were TGase-4 positive
(Figure 3 right). It is interesting to observe that interaction
between TGase-4 and beta1-integrin was weaker than that
with FAK and paxillin (Figure 3 right). Together, it suggests
that FAK is a key downstream event in TGase-4 activated
cell-matrix adhesion.
TGase-4 core domain was critical in TGase-4 mediated
cell-matrix adhesion
To further understand the nature of TGase-4 mediated
matrix adhesion, PC-3 cells were transfected with plas-
mids that coded different domains of TGase-4 protein
(Figure 4A/B). All 4 sublines that expressed TGase-4 core
domains, namely, PC3TG4ΔN, PC3TG4ΔC, PC3TG4CoreLarge
and PC3TG4CoreSmall, showed a significant increase in matrix
adhesion (Figure 4C/D), similar to that seen with the cell
over-expressing full length TGase-4. It is interesting to
observe that PC-3 cells expressing only Core domains had
a significant effect, whereas cells transfected with N- orC-domains but without the core domain (PC3TG4ΔC/core
and PC3TG4CoreLarge) did not have this effect. Finally,
TGase-4, TGase-4 core-domain mediated matrix adhesion
was abolished by PF-573228 (Figure 4C/D).
TGase-4 expression, localisation and co-localisation of
FAK, paxillin and integrin-1 in prostate cancer cells
In the light of the changes of cell-matrix adhesion after
over-expressing TGase-4 in the cells and the change of
their response to the FAK inhibitors, we went on to
test the pattern of FAK staining in these cells. Shown in
Figure 5A1, PC-3 cells, when over expressing TGase-4, ex-
hibit enhanced staining of the focal adhesion complexes. In
contrast, CA-HPV-10 wild type and transfection control
cells also had a clear pattern of FAK staining. This was di-
minished after losing TGase-4 (CA-HPV-10/ΔTGase4).
The staining of key components of a focal adhesion
complex, FAK, paxillin and integrin was further assessed in
PC-3/TGase4exp cells. Shown in Figure 5B are the staining
of the individual protein and their merge images. It is
clear that FAK, paxillin and beta1-integrin co-localised with
TGase-4 in the cells.
Expression of TGase-4 linked to the in vivo growth of
prostate tumours and the colocalisation of FAK, paxillin
and integrin-1 in prostate tumour tissues
Using athymic nude mice model, it was shown that prostate
cancer cells over-expressing TGase-4 had a significantly fas-
ter rate of growth [p = 0.05, by two-way ANOVA on rank]
(Figure 6, top left).
From the PC-3 tumour xenografts, we stained TGase-4,
FAK and Paxillin using phosphospecific antibodies. As
shown in Figure 6 [top right panel]. TGase-4 expressing
tumours had a positive staining of TGase-4 in the cytosol
and at the cell periphery (arrows). Here, we observed an in-
teresting pattern in which both total FAK and total Paxillin
were positively stained in the tumour cells in control tu-
mours and in TGase-4 expressing tumours. However, it is
very interesting to observe that phospho-FAK and phospho-
Paxillin are clearly seen in TGase-4 expressing tumours and
virtually invisible in control tumours (Figure 6 top right).
Similarly, we observed co-staining all three FAC proteins,
FAK, paxillin and integrin with TGase-4 in a panel of fro-
zen sections of human prostate tissues. Shown in Figure 6
are some representative images. Previously indicated and
suspected from the nature of TGase-4, TGase-4 staining
can be seen both intracellularly and in the matrix (Figure 6
bottom panel). All three FAC proteins are clearly detected
in the tissues, and have a high degree of co-localisation with
TGase-4 (Figure 6 bottom panel, composite panels).
Discussion
In the present study, we examined the possible relationship
between TGase-4, a prostate specific transglutaminase-4,
Figure 2 FAK small inhibitor and cell-matrix adhesion. A: Effect of FP-573228 on the adhesion of genetically modified PC-3 cells. a/b/c: cell
treated with medium alone; d/e/f: cells treated with FP-573228 (5nM). All three cells responded to the FAK inhibitor FP-573228 by reducing the
adhesiveness. The inhibitory effect is particularly strong with PC-3TGase4exp cells. B: Adhesion as calculated using the Rb model. C: The effect of
FP-573228 on exogenous TGase-4 induced adhesion in PC-3 control cells. rhTGase-4 significantly increased the adhesiveness which was reverted
by FP-573228. D: The effect of FP-573228 on exogenous TGase-4 induced adhesion in CA-HPV-10. * p < 0.05 vs no-treatment control of the same
cell; ** p < 0.05 vs wile type and control cells.
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shown an important biological link between TGase-4
and the focal adhesion complex (FAC), namely FAK and
paxillin in prostate cancer cells and prostate tissues. We
view that these findings have important biological impli-
cations in prostate cancer and in the design of therapies
of prostate cancer.The finding that TGase-4 is associated with cell-matrix
adhesion is not totally surprising. First, previous reports
have shown that TGase-4 is connected with the migration
and invasiveness of prostate cancer cells [6,7], two cellular
functions closely linked to cell-matrix adhesion; second,
other members of the TGase family, namely TGase-2 has
also been shown to regulate cell-matrix adhesion. Thus,
Figure 4 TGase-4 protein domains and cell-matrix adhesion. PC-3 cells were transfected with a series of plasmids that coded mutant TGase-4
with either TGase-N domain deleted, N- and core- domains deleted, TGase-C domain deleted, C- and core-domains deleted, the short core
domain or the large core domain (A and B). Cell adhesion after transfection was determined using ECIS in the absence or presence of PF-573228
(C and D). PC-3 transfected with core domain containing domains (B/C/D/E) showed increased matrix adhesion, similar to that seen in cells
transfected with the full length TGase-4. Cells transfected with plasmids in which core domains (F/G) were deleted did not differ from control
cells. Increased adhesion mediated by TGase-4 full length, and core domains was inhibited by PF-573228. * p < 0.05 vs no-PF573228 control,
** p < 0.05 vs transfection control.
Figure 3 TGase-4 and the activation of the focal adhesion complex. LEFT: effect of exogenous TGase-4 on the activation of focal adhesion
proteins. Cells were first subject to serum hunger for 2 hours, before treated with: a-serum free medium; b-serum free medium with BSS/BSA
buffer; c-rhTGase-4 100 ng/ml and d-sodiium orthovanadate (with 0.1% hudrogen peroxide). After one hour, cells were pelleted and lysed.
Anti-FAK or anti-paxillin antibody was added to the protein lysate. Immunoprecipiate was separated on 8% SDS-PAGE gel and probed by PY20
antibody. Total cell lysate used for immunoprecipitation were probed by anti-GAPDH antibody as a load control. rhTGase-4 induced
phosphorylation of FAK particular in PC-3 cells, and also induced phosphorylation of paxillin. RIGHT: Interaction between TGase-4 and focal
adhesion complex proteins. Proteins from fresh frozen human prostate tissues (top) and from a TGase-4 positive CA-HPV-10 cells (bottom) were
precipitated with anti-FAK, anti-integrinb1, anti-paxillin or irrelevant antibody (negative control). The immunoprecipitates or total protein lysate
from prostate tissues (total lysate, used as a positive control) were separated by SDS-PAGE. TGase-4 was probed with an anti-TGase-4 monoclonal
antibody (MaxPaB, Abnova). FAK and paxillin were strongly associated with TGase-4, compared with integrin.
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Figure 5 Co-staining of TGase-4, FAK and paxillin in prostate cancer cells. A: Immunofluorescence staining of FAK in PC-3 (A1) and
CA-HPV-10 (A2) cells. Wild type and the transfection control PC-3 cells showed little staining of focal adhesion complex. However, TGase-4
transfected (PC3 TGase4exp) spread well over the matrix and displayed a characteristic staining of focal adhesion complex using the anti-FAK
antibody. B: PC3-TGase4exp cells: Localisation FAK (B1 left), paxillin (B1 middle), integrin-β1 (B1 right) and TGase-4 (B2), and co-localisation of
FAK/paxillin/integrin with TGase-4 (B3). All images were from PC-3 cells transfected with TGase-4 (PC-3 TGase4exp). FAK/paxillin/integrin
demonstrated a clear co-localisation with TGase-4 in the cells.
Jiang et al. Journal of Translational Medicine 2013, 11:269 Page 9 of 12
http://www.translational-medicine.com/content/11/1/269TGase-4 appears to share the function with TGase-2 in
regulating matrix adhesion of prostate cancer cells.
However, how TGase regulates the matrix adhesion is
not entirely clear. Here, we first showed that blocking
FAK by small inhibitor can block TGase-4 mediated
cell-matrix adhesion, suggesting that TGase-4 may well
affect focal adhesion complex.
The structure of TGase-4 is interesting. The protein has
a N- and C-TGase domains as well as a TGase core
domain. Transglutaminases has been shown to contain
fibronectin binding domain [23]. The later is particularly
interesting. Indeed, the present study has found that aneutralising antibody to integrin-β1 can abolish TGase-4
induced cell-matrix adhesion. Integrin-β1 interacts with
the extracellular matrix, including fibronectin. Together, it
is suggested that TGase-4 may interact with integrin and
initiate the cell-matrix adhesion sequences. This is indeed
confirmed by the observation that exogenous TGase-4
can induce the phosphorylation of both FAK and paxillin.
In deciphering the contribution of different domains to
the matrix adhesion, we discovered that the matrix adhe-
sion activities of TGase-4 reside in the TGase-4 core do-
main, as all the constructs coded core domains have
matrix adhesion promoting actions, whereas deleting the
Figure 6 Effect of TGase-4 on tumour growth in vivo and localisation and co-localisation of TGase-4 and the focal adhesion complex
proteins. TOP panel: far left - TGase-4 and in vivo growth of tumours. PC-3 over-expressing TGase-4 cells grow significantly faster than control
cells (shown are medians). IFC panels: immunofluorescence staining of TGase-4, phosho-FAK, FAK, phospho-Paxillin and Paxillin (left to right) in
control and TGase-4 expression PC3 tumour xenograft. TGase-4: Tumours from PC3/TGase4 cells displayed staining of TGase-4 in the cytoplasmic
region as well as in the cell peripheries (arrows). Control tumours were negative for TGase-4 staining and mostly missing pFAK and pPaxillin
staining, although they are positive for FAK and Paxillin. PC3/TGase4 were seen to stain both pFAK and pPaxillin as well as stain strongly for total
FAK and Paxillin (arrows). BOTTOM panel: Immunofluorescence co-staining of FAK (left), paxillin (middle) and β1-integrin (right) with TGase-4 in
human prostate tissues. Shown in each panel are the match images of FAK/paxillin/integrin, TGase-4 and nucleus staining (Hoescht33528), and
the merged image between FAK, paxillin, or integrin and TGase-4. TGase-4 staining appeared in both cells and matrix. There co-localisations of
the FAC proteins and TGase-4 were seen in the tissues.
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The TGase-4 core domain shares a high amino acid hom-
ology with the core domains of TGase-1 and TGase-2.
TGase-2 has been shown to be a key matrix regulator in
cells. Together, TGase-4 core domain plays a central role in
TGase-4 mediated cell matrix adhesion in prostate cancer
cells. Collectively, the present study shows that TGase-4
may directly activate the cell-matrix adhesion sequence and
increase the adhesiveness of prostate cancer cells.
Although TGase-4 has been discovered for over a dec-
ade, its pattern of distribution in the prostate gland is
not clear, with matrix and cellular distribution being in-
dicated [4,24,25]. The present study and recent literature
have shown that TGase-4 is stained in both extracellular
matrix and intracellularly. It is also noteworthy that both
in cell culture and in prostate tissues, TGase-4, FAK,
Paxillin and integrin showed a pattern of co-localisation.
This is interesting as it indicates that the close proximity
of these proteins may present a mechanism by which
over-expression of TGase-4 in prostate cancer tissues
may increase the matrix adhesiveness of prostate cancercells. This is strongly supported by the observation that
TGase-4 positive xenografts had activated FAK and Paxillin
(pFAK and pPaxillin positive staining) on comparison to
control tumours in which FAK and Paxillin were present
but remain less active (less pFAK and pPaxillin staining).
This finding is highly interesting and has not been re-
ported with other transglutaminases, although it has been
indicated that FAK may be involved in the induction of
tissue transglutaminses by hyaluronic acid [26] Presently,
although the String search has predicted a possible
interaction between TGase-4 and vimentin, the function[s]
of the intracellular TGase-4 is not known and warrants
further investigation (Additional file 1).
The connection between TGase-4 and cell-matrix
adhesion is very interesting from a therapeutic point of
view. Already shown in the present study, inhibitor to
FAK is able to revert TGase-4-induced matrix adhesion
of prostate cancer cells. Genetic manipulation of FAK
can inhibit tumour growth [27]. FAK inhibitor is pres-
ently in clinical trials in treating a number of human
solid tumours [28-30]. Although the inhibitor is yet to
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clearly shows that FAK inhibitor may have an import-
ant implication in the treatment of prostate cancer and
that the levels of TGase-4 in prostate cancer may be
one of the determining factors to the sensitivity of the
patients to FAK inhibitor.
In conclusion, Prostate Transglutaminase, TGase-4, a
protein uniquely expressed in human prostate gland, plays
an important role in mediating cell-matrix adhesion of
prostate cancer cells. This effect is possibly mediated by the
Core domain of the protein and requires the participation
of integrin medicated focal adhesion kinase pathway.
The findings have an important implication in devising
treatment in prostate cancer. For example, the levels of
TGase-4 may be a factor in deciding the response of a
patient to FAK inhibitors as well as itself being a thera-
peutic target. The full clinical implication of TGase-4
is now open for investigation.
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